SARS-CoV-2 Spike Recombinant antibody
SARS-CoV-2 Spike Recombinant Antibody for ELISA, Neutralization
Host / Isotype
Human / IgG1
Reactivity
Virus
Applications
ELISA, Neutralization
Conjugate
Unconjugated
CloneNo.
AM001414
Cat no : 91361-PTG
Synonyms
Validation Data Gallery
Tested Applications
Positive Neutralization detected in | pseudotyped virus |
Positive ELISA detected in | SARS-CoV-2 Spike RBD protein |
Recommended dilution
Application | Dilution |
---|---|
Sample dependent. To be determined by the end user. |
Note: Proteintech is partnering with Active Motif to bring these cutting-edge, patient derived antibodies to our customers during this important time for COVID-19 research.
Product Information
91361-PTG targets SARS-CoV-2 Spike in ELISA, Neutralization applications and shows reactivity with Virus samples.
Tested Reactivity | Virus |
Host / Isotype | Human / IgG1 |
Class | Recombinant |
Type | Antibody |
Immunogen | Virus |
Full Name | SARS-CoV-2 Spike Protein |
Calculated Molecular Weight | 141 kDa |
GenBank Accession Number | NC_045512 |
Gene Symbol | SARS-COV-2 |
Gene ID (NCBI) | 43740568 |
RRID | AB_2882954 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Protein A Chromatography |
Storage Buffer | 140 mM Hepes, pH 7.5, 70 mM NaCl, 32mM NaOAc, 0.035% sodium azide, and 30% glycerol. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
COVID-19, which is short for coronavirus disease 2019, is the official name of the respiratory disease caused by infection with the novel coronavirus SARS-CoV-2. The virus that causes COVID-19 was named SARS-CoV-2 because it is a coronavirus genetically similar to, yet distinct from, the virus that caused the severe acute respiratory syndrome (SARS) outbreak in 2003. Studying the details of how this virus replicates and causes the disease will allow scientists and physicians to more rapidly develop fast and accurate methods of detection as well as to deploy therapeutic and vaccine strategies. This antibody was derived from COVID-19 patients who have cleared the virus. Patient serum IgG was sequenced and expressed as full-length IgG1 with human immunoglobulin heavy and light chains in mammalian 293 cells.